Research Reports | Market Assessment
August 2017

Non-Small-Cell Lung Cancer | Access and Reimbursement | US | 2017

Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the utilization of therapies through controls such as prior authorization, step therapy, and limits on prescription supplies. Increasingly, utilization management is being applied not only to drugs obtained from pharmacies but also to those administered by medical professionals and covered under their insured patients’ medical benefit. The entry of several novel agents targeting non-small-cell lung cancer (NSCLC), particularly the new immune checkpoint inhibitors, makes the NSCLC market ripe for examination of utilization management strategies. Presenting data from surveys of 39 MCOs and 100 oncologists, this access and reimbursement content analyzes the reimbursement environment for eight of the most promising new therapies for metastatic NSCLC and how MCO formulary decisions and utilization controls on both the pharmacy benefit and medical benefit affect prescribing by surveyed oncologists.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports